- Home
- TBPH vs ASGI Comparison
TBPH vs ASGI Comparison
Compare TBPH & ASGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- ASGI
- Stock Information
- Founded
- TBPH 2013
- ASGI 2019
- Country
- TBPH United States
- ASGI United States
- Employees
- TBPH N/A
- ASGI N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- ASGI Investment Managers
- Sector
- TBPH Health Care
- ASGI Finance
- Exchange
- TBPH Nasdaq
- ASGI Nasdaq
- Market Cap
- TBPH 452.3M
- ASGI 501.0M
- IPO Year
- TBPH N/A
- ASGI N/A
- Fundamental
- Price
- TBPH $9.32
- ASGI $18.00
- Analyst Decision
- TBPH Buy
- ASGI
- Analyst Count
- TBPH 4
- ASGI 0
- Target Price
- TBPH $13.75
- ASGI N/A
- AVG Volume (30 Days)
- TBPH 202.5K
- ASGI 83.3K
- Earning Date
- TBPH 02-26-2025
- ASGI 01-01-0001
- Dividend Yield
- TBPH N/A
- ASGI 8.76%
- EPS Growth
- TBPH N/A
- ASGI N/A
- EPS
- TBPH N/A
- ASGI N/A
- Revenue
- TBPH $63,192,000.00
- ASGI N/A
- Revenue This Year
- TBPH $11.41
- ASGI N/A
- Revenue Next Year
- TBPH $37.36
- ASGI N/A
- P/E Ratio
- TBPH N/A
- ASGI N/A
- Revenue Growth
- TBPH 15.93
- ASGI N/A
- 52 Week Low
- TBPH $7.44
- ASGI $14.96
- 52 Week High
- TBPH $10.90
- ASGI $18.55
- Technical
- Relative Strength Index (RSI)
- TBPH 47.75
- ASGI 50.98
- Support Level
- TBPH $8.85
- ASGI $18.02
- Resistance Level
- TBPH $10.05
- ASGI $18.29
- Average True Range (ATR)
- TBPH 0.38
- ASGI 0.19
- MACD
- TBPH 0.01
- ASGI 0.05
- Stochastic Oscillator
- TBPH 38.75
- ASGI 53.91
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About ASGI abrdn Global Infrastructure Income Fund of Beneficial Interest
abrdn Global Infrastructure Income Fund is a non-diversified, closed-end management investment company. Its objective is to seek to provide a high level of total return with an emphasis on current income by investing in assets that provide necessary services to society.